1,3-diphenyl-N-(prop-2-yn-1-yl)-1H-pyrazole-4-carboxamide | 1170483-36-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1,3-diphenyl-N-(prop-2-yn-1-yl)-1H-pyrazole-4-carboxamide
• 英文别名: 1,3-Diphenyl-N-2-propyn-1-yl-1H-pyrazole-4-carboxamide；1,3-diphenyl-N-prop-2-ynylpyrazole-4-carboxamide
• CAS: 1170483-36-9
• 化学式: C₁₉H₁₅N₃O
• 分子量: 301.348
• InChiKey: GVHSUNOYDSGFQR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  46.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1,3-diphenyl-N-(prop-2-yn-1-yl)-1H-pyrazole-4-carboxamide 、 4-trifluoromethylbenzyl azide 在 copper(ll) sulfate pentahydrate 、 sodium ascorbate 作用下， 以 水 、 叔丁醇 为溶剂， 反应 12.0h， 以81%的产率得到1,3-diphenyl-N-((1-(4-(trifluoromethyl)benzyl)-1H-1,2,3-triazol-4-yl)methyl)-1H-pyrazole-4-carboxamide
  参考文献：
  名称：

  Design, synthesis and biological evaluation of N -((1-benzyl-1 H -1,2,3-triazol-4-yl)methyl)-1,3-diphenyl-1 H -pyrazole-4-carboxamides as CDK1/Cdc2 inhibitors

  摘要：

  A series of new (N4(1-benzyl-1H-1,2,3-triazol-4-yl)methyl)-1,3-diphenyl-1H-Pyrazole-4-carboxamide derivatives (8-35) were designed, synthesized and evaluated as CDK1/Cdc2 inhibitors. Biological evaluation assays indicated that compounds 16 and 27 showed the most potent growth inhibitory activity against human cancer cell lines (MIAPaCa-2, MCF-7 and HeLa) with GI(50) values ranging from 0.13 to 0.7 mu M, compared with the positive control nocodazole (0.81-0.95 mu M). Flow cytometric analysis revealed that these compounds induce cell cycle arrest in the G2/M phase and Western blot analysis suggested that compound treatment resulted in reduction of CDK1 expression levels in MCF-7 cell line. Moreover, the apoptosis inducing effect of the compounds was studied using Hoechst staining, Rhoda mine 123 staining (MMP), carboxy-DCFDA staining (ROS), Annexin V-FITC assay. Based on these studies, two compounds 16 and 27 have been identified as promising new molecules that have the potential to be developed as leads. (C) 2016 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2016.06.011
• 作为产物：
  描述：

  1,3-二苯-1H-吡唑-4-甲醛 在 potassium permanganate 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 potassium hydroxide 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 水 为溶剂， 反应 3.33h， 生成 1,3-diphenyl-N-(prop-2-yn-1-yl)-1H-pyrazole-4-carboxamide
  参考文献：
  名称：

  发现吡唑衍生物作为组蛋白赖氨酸特异性脱甲基酶5B（KDM5B / JARID1B）的细胞活性抑制剂

  摘要：

  KDM5B（也称为PLU-1和JARID1B）是2-氧戊二酸和Fe 2+依赖性加氧酶，可作为组蛋白H3K4脱甲基酶，是抑制肿瘤抑制因子（作为药物靶标）表达的关键参与者。在这里，我们介绍了通过基于结构的虚拟筛选和生化筛选发现吡唑衍生物化合物5的效果，针对KDM5B的IC 50为9.320μM，随后对其进行了优化以得到1-（4-甲氧基苯基）-N-（2-甲基- 2-吗啉代丙基）-3-苯基-1H-吡唑-4-羧酰胺（27 ab），一种有效的KDM5B抑制剂，IC 50为0.0244μM 。在MKN45细胞中，化合物27 ab可以结合和稳定KDM5B并诱导H3K4me2 / 3（真正的KDM5B底物）积累，同时保持H3K4me1，H3K9me2 / 3和H3K27me2的含量不变。进一步的生物学研究还表明，化合物27 ab是一种有效的细胞活性KDM5B抑制剂，可以抑制MKN45细胞增殖，伤口愈合和迁移

  DOI：

  10.1016/j.ejmech.2020.112161

文献信息

• Design, synthesis and biological evaluation of N -((1-benzyl-1 H -1,2,3-triazol-4-yl)methyl)-1,3-diphenyl-1 H -pyrazole-4-carboxamides as CDK1/Cdc2 inhibitors
  作者：V. Ganga Reddy、T. Srinivasa Reddy、V. Lakshma Nayak、Budaganaboyina Prasad、Adiyala Praveen Reddy、A. Ravikumar、Shaik Taj、Ahmed Kamal

  DOI：10.1016/j.ejmech.2016.06.011

  日期：2016.10

  A series of new (N4(1-benzyl-1H-1,2,3-triazol-4-yl)methyl)-1,3-diphenyl-1H-Pyrazole-4-carboxamide derivatives (8-35) were designed, synthesized and evaluated as CDK1/Cdc2 inhibitors. Biological evaluation assays indicated that compounds 16 and 27 showed the most potent growth inhibitory activity against human cancer cell lines (MIAPaCa-2, MCF-7 and HeLa) with GI(50) values ranging from 0.13 to 0.7 mu M, compared with the positive control nocodazole (0.81-0.95 mu M). Flow cytometric analysis revealed that these compounds induce cell cycle arrest in the G2/M phase and Western blot analysis suggested that compound treatment resulted in reduction of CDK1 expression levels in MCF-7 cell line. Moreover, the apoptosis inducing effect of the compounds was studied using Hoechst staining, Rhoda mine 123 staining (MMP), carboxy-DCFDA staining (ROS), Annexin V-FITC assay. Based on these studies, two compounds 16 and 27 have been identified as promising new molecules that have the potential to be developed as leads. (C) 2016 Elsevier Masson SAS. All rights reserved.
• Discovery of pyrazole derivatives as cellular active inhibitors of histone lysine specific demethylase 5B (KDM5B/JARID1B)
  作者：Bing Zhao、Qianqian Liang、Hongmei Ren、Xinhui Zhang、Yang Wu、Kun Zhang、Li-Ying Ma、Yi-Chao Zheng、Hong-Min Liu

  DOI：10.1016/j.ejmech.2020.112161

  日期：2020.4

  KDM5B (also known as PLU-1 and JARID1B) is 2-oxoglutarate and Fe2+ dependent oxygenase that acts as a histone H3K4 demethylase, which is a key participant in inhibiting the expression of tumor suppressors as a drug target. Here, we present the discovery of pyrazole derivatives compound 5 by structure-based virtual screening and biochemical screening with IC50 of 9.320 μM against KDM5B, and its subsequent

  KDM5B（也称为PLU-1和JARID1B）是2-氧戊二酸和Fe 2+依赖性加氧酶，可作为组蛋白H3K4脱甲基酶，是抑制肿瘤抑制因子（作为药物靶标）表达的关键参与者。在这里，我们介绍了通过基于结构的虚拟筛选和生化筛选发现吡唑衍生物化合物5的效果，针对KDM5B的IC 50为9.320μM，随后对其进行了优化以得到1-（4-甲氧基苯基）-N-（2-甲基- 2-吗啉代丙基）-3-苯基-1H-吡唑-4-羧酰胺（27 ab），一种有效的KDM5B抑制剂，IC 50为0.0244μM 。在MKN45细胞中，化合物27 ab可以结合和稳定KDM5B并诱导H3K4me2 / 3（真正的KDM5B底物）积累，同时保持H3K4me1，H3K9me2 / 3和H3K27me2的含量不变。进一步的生物学研究还表明，化合物27 ab是一种有效的细胞活性KDM5B抑制剂，可以抑制MKN45细胞增殖，伤口愈合和迁移